Export Mendeley
＜journal article＞
Report of the Initial Outcome of Intensity-Modulated Radiation Therapy for Prostate Cancer
| Creator | |
|---|---|
| Language | |
| Publisher | |
| Date | |
| Source Title | |
| Vol | |
| Issue | |
| First Page | |
| Last Page | |
| Publication Type | |
| Access Rights | |
| JaLC DOI | |
| Abstract | Purpose : We started curative irradiation using intensity-modulated radiation therapy (IMRT) for prostate cancer from 2010. Forty eight patients who underwent IMRT at a total dose of 74Gy/37Fr were ex...amined retrospectively for their efficacy and safety. Materials and methods : Forty eight patients who underwent 74Gy/37Fr IMRT at our hospital from July 2012 to July 2014 were retrospectively examined. The details of patients were as below. T factor : T1/T2/T3/T4=25/15/7/1, Risk classification (NCCN) : low/intermediate/high/locally advanced very high=5/27/11/5, Age : 53 to 84 years old (median 73), Prostate specific antigen (PSA) before IMRT : under0.008 to 42.687 (median 6.450), Hormonal therapy : with/without =14/34. The observation period was 1.7 to 39 months (median 24.4). The treatment method was fixed 7 fields of IMRT for 45 cases, volumetric modulated arc therapy (VMAT) for 3 cases. In principle, planning target volume (PTV) mean prescription was used for planning. We examined for clinical/biochemical recurrence, and acute/late adverse events (CTCAE ver. 4.0) retrospectively. Results : No primary disease death was occurred. No clinical recurrence was observed, but biochemical recurrence was detected in one (2.1％). Adverse events as acute phase injuries, Grade 1-2 of frequent urination in 35 (72.9％), miction pain in 7 (14.6％), and Grade 2 of dysuria in one (2.1％) were observed. Grade 1 of rectal bleeding was appeared in 2 (4.2％) as late adverse events. No serious acute and late adverse effects (≧Grade 3) were occurred. Conclusion : Our clinical results of 74Gy/37Fr IMRT showed favorable efficacy and safety compared with past reports, however the observation period was rather short. Based on this results, IMRT is currently performed with the increased total dose of 78Gy/39Fr for intermediate and high risk prostate cancer.show more |
| Table of Contents | はじめに 目的 対象と方法 対象 方法 結果 考察 結論 参考文献 |
Hide fulltext details.
| File | FileType | Size | Views | Description |
|---|---|---|---|---|
p008
|
8.07 MB | 2,480 |
Details
| PISSN | |
|---|---|
| NCID | |
| Record ID | |
| Peer-Reviewed | |
| Subject Terms | |
| Type | |
| Created Date | 2018.06.19 |
| Modified Date | 2021.03.03 |